Hemogenyx Pharmaceuticals

HemoGenyx LLC is a biopharmaceutical company focused on developing innovative treatments for blood diseases, including leukemia and lymphoma. Established in 2013 and based in Brooklyn, New York, the company leverages a unique class of adult hemogenic endothelial cells to generate cancer-free hematopoietic stem cells (HSC) for use in transplants. This approach aims to enhance the effectiveness of bone marrow transplants and address the limitations associated with traditional donor dependency. HemoGenyx is also advancing products such as a bi-specific antibody and CAR-T therapy, targeting relapsed and refractory acute myeloid leukemia and acute lymphoblastic leukemia. As a subsidiary of Hemogenyx Pharmaceuticals Ltd, the company is committed to transforming the landscape of blood disease treatment through its cutting-edge technologies.